AstraZeneca (AZN-0.67%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals . The only hurdle left to jump is obtaining approval from United Kingdom regulators.

The transaction values Alexion at $175 per share, a sizeable 45% premium on its closing price on Friday, the day before the deal was announced. Alexion shareholders will receive $60 in cash, plus ...

Just as any takeover target would, Alexion asked AstraZeneca to increase its buyout offer several times before the two shook hands on the $39 billion deal unveiled in December.

Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

Under the terms of the deal, AstraZeneca will pay $60 in cash and 2.1243 of its American depositary receipts for each of Alexion’s shares. That amounts to $175 a share, a nearly 45 percent ...

(RTTNews) - Wednesday, Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for Koselugo for the ...

AstraZeneca PLC AZN has struck a deal to buy a portfolio of gene therapies from Pfizer Inc. PFE for up to $1 billion, ... CEO of Alexion, AstraZeneca’s rare-disease unit, ...

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). The only hurdle left to jump is obtaining approval from United Kingdom regulators.

Drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid-19 pandemic.